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Abstract
Background: Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected
injection and non-injection drug users (IDUs) in Kenya remains elusive.
Methods: A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted
among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48),
and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages
were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma
samples and genotypes established by nested-PCR and direct sequencing.
Results: HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1
infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly,
HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected
IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1
infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected
non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic
(5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected
IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response
stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected
(6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates
were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected
(7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing
minimal diversity was detected among the study participants.
Conclusion: HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections.
Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative
IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high
and low risk populations of Kenya.
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Background
Despite existence of an effective vaccine, about 2 billion
people have been exposed to hepatitis B virus (HBV)
leading to at least 300 million chronic HBV infections
and 0.6 million deaths worldwide [1]. The problem is
further compounded by the spreading co-endemicity
with HIV-1 leading to at least three million co-infections
in the world [2]. The higher rates of HBV and HIV-1 co-
infections are driven by the shared portals of entry such
as parenteral, perinatal and sexual routes [3].
Hepatitis B virus sero-prevalence is determined by
examining for the presence of hepatitis B surface antigen
(HBsAg), hepatitis B surface antibody (HBsAb), hepatitis
B pre-core antigen (HBeAg), hepatitis B pre-core anti-
body (HBeAb) and hepatitis B core antibody (HBcAb)
sero-marker reactivity [4]. HBsAg represent active acute
or chronic infection, HBeAg indicate high viral replica-
tion and persistence while HBsAb and HBeAb signify
hepatitis B resolution [4, 5]. HBcAb is a non-protective
total antibody of the classes IgM and IgG denoting
acute-window and past infection, respectively [4]. To
our knowledge, no study has estimated HBV sero-
prevalence by concurrent testing of the five hepatitis B
virus sero-markers in Kenya.
The incubation period following HBV exposure varies
from one to six months and correlates with magnitude
of the inoculum [6]. Resolution and outcomes of HBV
infection are governed by host immunity, age, gender,
infection route and genotype [7]. While immune compe-
tent individuals successfully resolve HBV infection [8],
immune-suppressed subjects such as HIV-1 infected pa-
tients rapidly progress from acute to chronic stages [9].
Although most individuals recover from acute or mild
infections, occult infection persists in the liver with
reactivation largely occurring in immune-suppressed in-
dividuals [10]. In Sub-Saharan Africa, HBV and HIV-1
are co-endemic [11], but information about HBV infec-
tion stages in HIV-1 infected and uninfected injection
drug users (IDUs) and non-IDUs is unknown.
To date, ten genotypes (A-J) of HBV have been re-
ported with Africa having mainly genotype A and to a
varying extend genotypes C, D and E [12]. Although
genotype A is the most common in blood donors, com-
mercial sex workers and HIV-1 infected patients on anti-
retroviral treatment (ART) in Kenya, genotypes D and E
occur less frequently [13–17]. HBV genotypes influence
disease severity and response to antiviral treatment, and
cluster with risk-population [10, 18]. However, circulat-
ing HBV genotypes in most-at-risk populations (MARP)
in Kenya particularly among IDUs and non-IDUs re-
mains elusive. This study, therefore, examined hepatitis
B virus sero-markers, infection stages and genotype dis-
tribution in HIV-1 infected and uninfected IDUs and
non-IDUs residing at Coastal Kenya.
Methods
Study area, design and population
A cross-sectional study of drug users was conducted at
Bomu Hospital, Mombasa, coastal Kenya. A description
of the study site and recruitment procedure is presented
elsewhere [19]. Injection drug users were defined as
individuals exhibiting needle-scars and reporting use of
any illicit injection drug from the United Nations Office
on Drugs and Crime (UNODC) report [20] for at least
once in the previous month. Non-injection drug users
were defined as persons who had never injected drugs
but have used at least one non-injection drugs listed in
the UNODC report [20]. The study participants were
stratified into HIV-1 infected and uninfected IDUs, HIV-1
infected and uninfected non-IDUs, and HIV-1uninfected
non-drug using controls (from the general population).
About, 3.5 mL venipuncture blood was collected in EDTA
BD vacutainerTM anticoagulant tubes (BD, Franklin Lakes,
USA) for HIV-1 serological testing, CD4+ T cell enumer-
ation and plasma harvesting as described elsewhere [19].
HBV sero-marker testing
The five HBV serological markers (HBsAg, HBsAb,
HBeAg, HBeAb and HBcAb-IgM) reactivity of plasma
samples was determined using the one-step HBV-5
panel rapid diagnostic cassette (Healthaw Medical lim-
ited, Hangzhou, China) according to the manufacturer’s
instructions. Briefly, 5 μL of the test plasma was placed
into each of the five sample wells corresponding to the
sero-markers. Two drops of buffer were added to each
well and HBV sero-marker reactivities recorded after
20 min.
Sequencing and genotyping
Hepatitis B virus DNA was extracted from acute and
chronic plasma samples using QiaAmp™ DNA Mini Kit
(Qiagen Inc., Valencia, USA) according to the manufac-
turer’s recommendations. Hepatitis B virus PreS1 gene
was amplified by nested polymerase chain reaction (PCR)
using GeneAmp™ PCR system 9700 (Applied Biosystems,
Foster City, USA). Each PCR reaction contained 12.5 μL
of 2x Phusion high-fidelity PCR master mixes, 1.25 μL of
each primer, 5 μL of DNA and DEPC-treated water in a
final volume of 25 μL. Amplification was performed using
the primers HBPr1 (position: 2850–2868, 5'-GGGTCACC
ATATTCTTGGG-3') and HBr135 (position: 803–822, 5'-
CAAAGACAAAAGAAAATTGG-3') for the first round,
and HBPr2 (position: 2867–2888, 5'-GAACAAGAGCTA
CAGCATGGG-3') and HBPr3 (position: 3226–3246, 95'-
CCACTGCATGG CCTGAGGATG-3') for the second
round [21]. The first and second round PCR conditions
were one cycle at 94 °C for 10 min, followed by 40 cycles
at 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 1 min, with
a final extension of 72 °C for 10 min. PCR products were
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visualized by an agarose gel electrophoresis method.
Purified DNA products were directly sequenced using
automated DNA sequencer ABI 377 (Applied Biosystems,
Foster City, USA), using fluorescence-labelled dideoxynu-
cleotide chain terminators (ABI Prism BigDye™ Termin-
ator Cycle Sequencing Reaction kit; Applied Biosystems).
About 1.25 μL of primers HBPr2 and HBPr3 were used
for forward and reverse sequencing reactions, respectively.
Pairwise contiguous sequences were generated using
DNA Baser Sequence Assembler version 4.20.0 (Heracle
Software, Germany). Consensus sequences were aligned
with complete HBV genotypes A-J reference sequences
from Genbank using ClustalW [22]. Phylogenetic analyses
was performed using MEGA version 6 [23].
Statistical analysis
Statistical analyses were performed using SPSS version
19.0 (IBM SPSS Statistics for Windows, Version 19.0.
Armonk, NY: IBM Corp.). Age and CD4+ T cell counts
were compared among groups using Kruskal Wallis test
followed by Dunn’s post-hoc correction for multiple
comparisons. Differences in the distribution of propor-
tions of gender, HBV sero-markers, infection stages and
genotypes were compared across the study groups using
the Chi-square tests. All tests were 2-tailed with statis-
tical significance set at a critical alpha value of 5 %.
Ethical considerations
The study was approved by Kenyatta University
Ethical Review Committee and was conducted ac-
cording to the Helsinki Declarations [24]. Written in-
formed consent was obtained from each participant
before enrolment and confidentiality was ensured in
the course of the study. All the study participants
were provided with free health education on sexually
transmitted infections (STIs) including HIV, hepatitis
B and C, tuberculosis, hygiene and nutrition. Partici-
pants testing positive for HIV were referred to the
comprehensive care centres at Bomu Hospital or the




The baseline characteristics of the study participants
are summarized in Table 1. A total of 752 adults were
recruited into the study. The study participants were
categorized into the following five study groups: 1)
HIV-1 infected IDUs (n = 157); 2) HIV-1 uninfected
IDUs (n = 214); 3) HIV-1 infected non-IDUs (n = 139);
4) HIV-1 uninfected non-IDUs (n = 48) and HIV-1
negative non-drug users (n = 194). HIV-1 uninfected IDUs
(6.5 %) had fewer females compared to HIV-1 infected
IDUs (54.8 %), HIV-1 infected non-IDUs (60.4 %), HIV-1
uninfected non-IDUs (39.6 %) and HIV-1 uninfected non-
drug users (58.8 %; P < 0.0001). Age varied significantly
across the study groups (P < 0.0001) with HIV-1 infected
non-IDUs being older (median, 36.0; IQR, 14.5) than
HIV-1 uninfected non-IDUs (median, 30.4; IQR, 11.8),
and non-drug users (median, 30.8; IQR, 12.8; P < 0.001).
CD4+ T cell counts were significantly different across the
groups (P < 0.0001) such that HIV-1 infected IDUs (me-
dian, 456; IQR, 449) presented with lower counts rela-
tive to HIV-1 uninfected non-drug users (median, 831;
IQR, 513), HIV-1 uninfected non-IDUs (median, 809;
IQR, 486), HIV-1 infected non-IDUs (median, 553;
IQR, 479) and HIV-1 uninfected IDUs (median, 905;
IQR, 641; P < 0.001). In addition, HIV-1 infected non-
IDUs (median, 553; IQR, 479) had lower CD4+ T cell
counts compared to HIV-1 uninfected non-drug users
(median, 831; IQR, 513), HIV-1 uninfected non-IDUs
(median, 809; IQR, 486) and HIV-1 uninfected IDUs
(median, 905; IQR, 641; P < 0.001).
Hepatitis B viral marker distribution
Hepatitis B sero-marker reactivities in the study partici-
pants are shown in Table 2. HBsAg positivity rates were
significantly higher in HIV-1 infected IDUs (9.6 %) com-
pared to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected
non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %)
and HIV-1 uninfected non-drug users (2.6 %; P = 0.002).
Interestingly, rates of HBsAb positivity were significantly
higher in HIV-1 uninfected IDUs (16.8 %) and HIV-1
uninfected non-IDUs (14.6 %), in comparison to HIV-1 in-
fected IDUs (8.3 %), HIV-1 infected non-IDUs (8.6 %) and
Table 1 Baseline characteristics of the study participants
Non-drug users Non-injection drug users Injection drug users
Characteristic HIV-1(−), n = 194 HIV-1(−), n = 48 HIV-1(+), n = 139 HIV-1(−), n = 214 HIV-1(+), n = 157 P
Females, n (%) 114 (58.8) 19 (39.6) 84 (60.4) 14 (6.5) 86 (54.8) <0.0001
Age, yrs. 30.8 (12.8) 30.4 (11.8) 36.0 (14.5)a,b 31.7 (9.1) 30.6 (6.5) <0.0001
CD4+ T cells/μL 831 (513) 809 (486) 553 (479)a,b,c 905 (641) 456 (449)a,b,c <0.0001
Data shown are number (n) and proportions (%) of subjects for gender and medians (IQR, interquartile range) for age and CD4+ T cell counts. Statistical
comparison of proportions among groups was conducted by Chi-Square test. Age and CD4+ T cell comparisons across groups were performed using Kruskal Wallis
test followed by Dunn’s post-hoc test for multiple comparisons. HIV-1(+), human immunodeficiency virus-1 infected, HIV-1(−) uninfected. aP < 0.001 vs. non-drug
users; bP < 0.001 vs. HIV-1(−) non-injection drug users; and cP < 0.001 vs. HIV-1(−) injection drug users
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HIV-1 uninfected non-drug users (8.2 %; P = 0.023). Al-
though only 1 (0.13 %), HBeAg positive reaction was de-
tected among the study groups, rates of HBeAb positivity
were similar across study groups (P = 0.186). Consistent
with the pattern observed for HBsAg reactivity, HBcAb-
IgM positivities were higher in HIV-1 infected IDUs
(10.2 %) compared to HIV-1 uninfected IDUs (3.3 %),
HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-
IDUs (2.1 %) and HIV-1 uninfected non-drug users (4.6 %;
P = 0.038).
Hepatitis B infection stages
HBV infection stages are summarized in Table 2. Rates
of acute infection (5.7 %) was higher in HIV-1 infected
IDUs versus HIV-1 uninfected IDUs (1.4 %), HIV-1
infected non-IDUs (0.0 %), HIV-1 uninfected non-IDUs
(0.0 %) and HIV-1 uninfected non-drug users (1.5 %).
Likewise, higher rates of chronic infection were detected
in the HIV-1 infected IDUs (5.1 %) compared to HIV-1
uninfected IDUs (0.9 %), HIV-1 infected non-IDUs
(3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and HIV-1
uninfected non-drug users (1.5 %). In addition, signifi-
cantly higher rates of vaccine type response was detected
in HIV-1 uninfected IDUs (15.4 %) in comparison to
HIV-1 infected IDUs (6.4 %), HIV-1 infected non-IDUs
(6.5 %), HIV-1 uninfected non-IDUs (10.4 %) and HIV-1
uninfected non-drug users (5.7 %; P = 0.003). Moreover,
rates of past or resolved infection were non-significantly
higher in the HIV uninfected injection drug users (11.2 %)
compared to HIV-1 infected IDUs (8.3 %), HIV-1 infected
non-IDUs (7.2 %), HIV-1 uninfected non-IDUs (6.3 %)
and HIV-1 uninfected non-drug users (6.7 %; P = 0.479).
Overall, frequencies of susceptible individuals were signifi-
cantly higher in HIV-1 uninfected non-drug users
(84.5 %), HIV-1 infected non-IDUs (82.7 %), and HIV-1
uninfected non-IDUs (83.3 %) compared to HIV-1
infected IDUs (74.5 %) and HIV-1 uninfected IDUs
(71.0 %; P = 0.005). Thus, HBV exposure rates were
15.5 %, 17.3 %, 16.7 %, 25.5 % and 29.0 %, respectively, in
HIV-1 uninfected non-drug users, HIV-1 infected non-
IDUs, HIV-1 uninfected non-IDUs, HIV-1 infected IDUs
and HIV-1 uninfected IDUs.
HBV genotypes
From a total of 33 individuals with acute (n = 15) and
chronic (n = 18) stages, 23 (acute, n = 12 and chronic, n
= 11) were successfully sequenced (Table 2). Only HBV
genotype A subgenotype A1 were detected among the
study groups. Rates of the A1 genotypes were 6.4 %,
1.9 %, 2.2 % and 3.1 % in HIV-1 infected IDUs, HIV-1
uninfected IDUs, HIV-1 infected non-IDUs, and HIV-1
uninfected non-drug users, respectively. In addition,
phylogenetic analysis of the 23 isolates indicated min-
imal diversity (Fig. 1).
Table 2 Hepatitis B virus sero-reactivities, infection stages and genotypes in the study participants
Non-drug users Non-injection drug users Injection drug users
HIV-1(−), n = 194 HIV-1(−), n = 48 HIV-1(+), n = 139 HIV-1(−), n = 214 HIV-1(+), n = 157 P
Sero-marker
HBsAg 5 (2.6) 0 (0.0) 5 (3.6) 5 (2.3) 15 (9.6) 0.002
HBsAb 16 (8.2) 7 (14.6) 12 (8.6) 36 (16.8) 13 (8.3) 0.023
HBeAg 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) -
HBeAb 13 (6.7) 3 (6.3) 13 (9.4) 26 (12.1) 21 (13.4) 0.186
HBcAb-IgM 9 (4.6) 1 (2.1) 9 (6.5) 7 (3.3) 16 (10.2) 0.038
Infection stage
1 3 (1.5) 0 (0.0) 0 (0.0) 3 (1.4) 9 (5.7) -
2 3 (1.5) 0 (0.0) 5 (3.6) 2 (0.9) 8 (5.1) -
3 11 (5.7) 5 (10.4) 9 (6.5) 33 (15.4) 10 (6.4) 0.003
4 13 (6.7) 3 (6.3) 10 (7.2) 24 (11.2) 13 (8.3) 0.479
5 164 (84.5) 40 (83.3) 115 (82.7) 152 (71.0) 117 (74.5) 0.005
HBV genotypes
A1 6 (3.1) 0 (0.0) 3 (2.2) 4 (1.9) 10 (6.4) -
Data shown are number (n) and proportions (%) of subjects. HIV-1(+), human immunodeficiency virus-1 infected, HIV-1(−) uninfected. HBsAg, hepatitis B surface
antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e-antigen; HBeAb, hepatitis B e-antibody; HBcAb-IgM, hepatitis B core antibody Immunoglobulin
M. Statistical comparison was performed using Pearson’s Chi-square test where appropriate. Hepatitis B sero-marker test results were used to categorize hepatitis
B virus infection status in to five (1–5) infection stages based on previous classifications [4, 5, 42, 43] as follows: 1 = Acute (HBsAg+, HBsAb-, HBeAg+/−, HBeAb-,
HBcAb-IgM+/−); 2 = Chronic (HBsAg+, HBsAb+/−, HBeAg+/−, HBeAb+, HBcAb-IgM+/−); 3 = Vaccine type response (HBsAg-, HBsAb+, HBeAg-, HBeAb-, HBcAb-IgM-);
4 = Past, resolved or occult infection (HBsAg-, HBsAb+/−, HBeAg-, HBeAb+/−, HBcAb-IgM+/−); 5 = Uninfected (HBsAg-, HBsAb-, HBeAg-, HBeAb-, HBcAb-IgM-)
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Discussion
Hepatitis B sero-markers, infection stages and genotypes
are integral in selecting, initiating and monitoring re-
sponse to treatment and in sero- and molecular epide-
miologic surveillance [8, 25]. Although HBV exhibits
geographic and risk-group clustering of genotypes [18],
distribution of HBV genotypes in HIV-1 mono- and co-
infected injection and non-injection drug users from Af-
rica is largely unknown. This study examined HBV sero-
marker reactivity, infection stages and genotypes among
Fig. 1 Phylogenetic tree of HBV isolates. Neighbour-Joining method based on 1000 bootstrap replicates and p-distances were used for generating
the phylogenetic tree [23]. HBV genotype sequences from GenBank together with their country of origin and accession numbers are presented.
Wooly monkey HBV (AY226578-WMHBV) was used as the out-group. Relevant bootstrap values are indicated. HBV isolates from study participants
are indicated by diamond signs. The scale bar represents genetic distance
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HIV-1 infected and uninfected IDUs and non-IDUs resi-
dent at coastal Kenya.
The contrasting sero-positivity rates of HBsAg, HBsAb
and HBcAb-IgM in HIV-1 infected and uninfected IDUs
and non-IDUs reflect frequent HBV exposure to a
“competent” (HIV-1 uninfected IDUs) and “incompe-
tent” (HIV-1 infected IDUs) and less exposure to a
“competent” (HIV-1 negative non-IDUs) and “incompe-
tent” (HIV-1 positive non-IDUs) immune system. These
findings, are in part, consistent with previous studies il-
lustrating contrasting HBsAg, HBsAb and HBcAb posi-
tivity in HIV-1 infected and uninfected IDUs [26]. Most
importantly, the results also partly mirror HBsAg posi-
tivity rates of 7 % in HIV-1 infected female sex workers
from Mombasa (the same region as the current study
area) [13]. The lower rates of HBsAg positivity in the
HIV-1 negative IDUs and non-drug users, and HIV-1
infected non-IDUs may be linked to perinatal and/or
early childhood acquisition of HBV infection [27, 28].
However, the higher rates of HBsAg in the HIV-1
infected IDUs suggest secondary acquisition of HBV
post-HIV infection from increased high risk injection
and sexual practices that are prevalent among HIV
infected IDUs at Coastal Kenya [29]. While the under-
lying mechanisms remain undefined, it is possible that
depleted CD4+ T cell counts in HIV-1 infected IDUs,
cause diminished HBsAg sero-conversion and antibody
production [30]. HBeAg and HBeAb rates observed in
this study are partly consistent with previous studies
among HIV-1 positive Nigerian women and Czech
IDUs [31, 32]. Altogether, these findings suggest an
altered host response to HBV infection in HIV-1 in-
fected and uninfected IDUs and non-IDUs from coastal
Kenya.
Although complete serological testing of the five
hepatitis B virus sero-markers (HBsAg, HBsAb, HBeAg,
HBeAb and HBcAb) is key in guiding accurate diagno-
sis and infection staging of hepatitis B virus [4, 5], to
our knowledge, this is the first study to examine utility
of the five hepatitis B virus sero-markers in identifying
the infection stages of HBV infections in HIV-1 in-
fected and uninfected IDUs and non-IDUs from Kenya.
Although the sensitivity and specificity of various HBV
rapid diagnostic tests varies [33, 34], acute hepatitis B
infection rates of 5.7 % in the HIV-1 infected IDUs
were detected. This finding corroborates with previous
studies showing acute hepatitis B virus infection rates
of 5.1 % in IDUs from a high HIV-1 risk region of
Scotland [35]. In addition, chronic hepatitis B virus in-
fection rates identified in this study are comparable
with rates among HIV-1 infected IDUs in the United
States of America [36], and female sex workers from
Mombasa (a most-at-risk population from the same
study area as the current study) [13]. Taken together,
the higher rates of acute and chronic hepatitis B virus
infection in HIV-1 infected IDUs suggest that HIV-1 in-
fection indirectly and/or directly increase the risk of ac-
quiring and developing hepatitis B virus infection in
IDUs. Our laboratory is currently investigating this
hypothesis.
Higher rates of vaccine type responses and resolved
infection stages in HIV-1 uninfected IDUs are related
to the higher CD4+ T cell counts recorded in these
study participants. These observations are similar to
previous vaccine-type response and resolved infection
rates, respectively, detected in young American and
Iranian IDUs [37, 38] and HIV-1 uninfected South Afri-
cans [39]. The higher CD4+ T cell counts are responsible
for increased HBV surface antigen recall responses [40],
and resolution of HBV infection [41] in HIV-1 infected
and uninfected individuals. Thus, incorporating immune
modulators and vaccine booster dose regimens may
greatly enhance immunity in co-infected individuals.
Only HBV genotype A sub-genotype A1 were detected
in all the study participants, supporting the stability and
persistence of this genotype in Kenya. This finding is in
line with previous findings in which only genotype A1 was
identified among HIV-1 infected adults on antiretroviral
therapy from Nairobi [17] and commercial sex-workers
from Mombasa [13]. The minimal genetic diversity in the
HBV A genotypes found in this study, suggest recent
introduction in the HIV-1 infected and uninfected popula-
tions of IDUs in Kenya.
Finally, it is important to outline the limitations of this
study. This cross-sectional study used HBcAb-IgM to
classify acute infection stages even though HBcAb-IgM
may persist for several years after acute infection [4].
While the sensitivity and specificity of the various HBV
rapid diagnostic tests varies [33, 34], nucleic acid testing
was performed on plasma samples obtained from study
participants presenting with acute and chronic infection
stages based on sero-profile. Even though prospective
studies would be important in examining HBV sero-
responses, genotypes, viral load and occult infections in
HIV-1 infected and uninfected IDUs and non-IDUs, this
cross-sectional study has delineated the value of the 5-
panel sero-markers in directing infection staging and
genotyping of HBV infections.
Conclusion
HBV 5-panel sero-marker testing is important in guiding
infection staging and genotyping of HBV infections.
Contrasting sero-reactivities characterized by higher
HBsAg and HBcAb positive rates and lower HBsAb
positive rates are associated with HIV-1 driven immune
suppression. Additionally, it is evident that genotype A
is the main circulating HBV infection among IDUs and
non-IDUs at coastal Kenya.
Webale et al. BMC Infectious Diseases  (2015) 15:299 Page 6 of 8
Availability of supporting data
GenBank accession numbers of sequences reported in
this study: KP407579, KP407580, KP407581, KP407582,
KP407583, KP407584, KP407585, KP407586, KP407587,
KP407588, KP407589, KP407590, KP407591, KP407592,
KP407593, KP407594, KP407595, KP407596, KP407597,
KP407598, KP407599, KP407600 and KP407601.
Phylogenetic data available from the Dryad Digital
Repository:http://dx.doi.org/10.5061/dryad.gq8pk
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TW and VB conceived and designed the study. TW, MKW and VB performed
data analyses and co-drafted the manuscript. AA, FOM, and RL were involved
in study design, and experimental analyses. AKN, NLMB and CO performed
bioinformatics analysis and critically reviewed the manuscript. All authors
have read and approved the manuscript.
Acknowledgements
We thank the study participants for their participation in the study. We are
grateful to the management and staff of Bomu Hospital for their support
during the study. This research was in part, supported by National
Commission on Science, Technology and Innovation (NCST/5/003/065) and
National Authority for the Campaign Against Alcohol and Drug Abuse.
Author details
1Department of Biomedical Sciences and Technology, Maseno University,
Maseno, Kenya. 2Department of Environment and Health Sciences, Technical
University of Mombasa, Mombasa, Kenya. 3Centre for Virus Research, Kenya
Medical Research Institute, Nairobi, Kenya. 4Department of Microbiology,
Kenyatta University, Nairobi, Kenya. 5Bomu Hospital, Mombasa, Kenya.
6Department of Biological Sciences, Embu University College, Embu, Kenya.
7African Population and Health Research Centre, Nairobi, Kenya. 8Department
of Medical Laboratory Sciences, Masinde Muliro University of Science and
Technology, P. O. Box 190–50100, Kakamega, Kenya.
Received: 8 January 2015 Accepted: 23 July 2015
References
1. WHO. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84(40):405–19.
2. Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver
disease in HIV patients. AIDS Rev. 2013;15(1):25–31.
3. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in
sub-Saharan Africa: an association between highly prevalent infectious
diseases. A systematic review and meta-analysis. Int J Infect Dis.
2010;14(12):e1024–31.
4. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B
virus. Can J Infect Dis Med Microbiol. 2005;16(2):65–72.
5. Mahoney FJ. Update on diagnosis, management, and prevention of
hepatitis B virus infection. Clin Microbiol Rev. 1999;12(2):351–66.
6. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical
hepatitis and time of appearance of hepatitis–associated antigen. Am J Med
Sci. 1972;263(1):27–33.
7. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a
complex relationship. World J Gastroenterol. 2014;20(30):10395–404.
8. Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and
therapeutic promise. Yonsei Med J. 2012;53(5):875–85.
9. Price J. An update on hepatitis B, D, and E viruses. Top Antivir Med.
2014;21(5):157–63.
10. Gerlich WH. Medical virology of hepatitis B: how it began and where we are
now. Virol J. 2013;10:239.
11. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and
impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in
Sub-Saharan Africa. J Clin Virol. 2014;61(1):20–33.
12. Zhang Q, Cao G. Genotypes, mutations, and viral load of hepatitis B virus
and the risk of hepatocellular carcinoma: HBV properties and
hepatocarcinogenesis. Hepat Mon. 2011;11(2):86–91.
13. Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, et al.
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection
in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One.
2013;8(3), e59346.
14. Kwange SO, Budambula NL, Kiptoo MK, Okoth F, Ochwoto M, Oduor M,
et al. Hepatitis B virus subgenotype A1, occurrence of subgenotype D4,
and S gene mutations among voluntary blood donors in Kenya. Virus
Genes. 2013;47(3):448–55.
15. Mwangi J, Nganga Z, Songok E, Kinyua J, Lagat N, Muriuki J, et al. Molecular
genetic diversity of hepatitis B virus in Kenya. Intervirology. 2008;51(6):417–21.
16. Ochwoto M, Chauhan R, Gopalakrishnan D, Chen CY, Ng'ang'a Z, Okoth F,
et al. Genotyping and molecular characterization of hepatitis B virus in liver
disease patients in Kenya. Infect Genet Evol. 2013;20:103–10.
17. Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, et al. HBV lamivudine
resistance among hepatitis B and HIV coinfected patients starting lamivudine,
stavudine and nevirapine in Kenya. J Viral Hepat. 2011;18(10):e447–52.
18. Araujo NM, Waizbort R, Kay A. Hepatitis B virus infection from an
evolutionary point of view: how viral, host, and environmental factors shape
genotypes and subgenotypes. Infect Genet Evol. 2011;11(6):1199–207.
19. Were T, Wesongah JO, Munde E, Ouma C, Kahiga TM, Ongecha-Owuor F,
et al. Clinical chemistry profiles in injection heroin users from Coastal
Region, Kenya. BMC Clin Pathol. 2014;14:32.
20. UNODC. World drug report 2014. Vienna: United Nations Office on Drugs
and Crime; 2014.
21. Stuyver LH, Rossau RE, Maertens GB. Method for Typing and Detecting HBV.
I. N.V., Editor. 2007, Innogenetics N.V., Ghent (BE): USA.
22. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The
CLUSTAL_X windows interface: flexible strategies for multiple sequence
alignment aided by quality analysis tools. Nucleic Acids Res.
1997;25(24):4876–82.
23. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular
Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725–9.
24. Parsa-Parsi RW, Ellis R, Wiesing U. Fifty years at the forefront of ethical
guidance: the world medical association declaration of helsinki. South Med
J. 2014;107(7):405–6.
25. Ranjbar R, Davari A, Izadi M, Jonaidi N, Alavian SM. HIV/HBV Co-Infections:
Epidemiology, Natural History, and Treatment: A Review Article. Iran Red
Crescent Med J. 2011;13(12):855–62.
26. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence,
patterns, and course of past hepatitis B virus infection in intravenous drug
users with HIV-1 infection. Am J Gastroenterol. 2000;95(5):1316–22.
27. Greenfield C, Osidiana V, Karayiannis P, Galpin S, Musoke R, Jowett TP, et al.
Perinatal transmission of hepatitis B virus in Kenya: its relation to the presence
of serum HBV-DNA and anti-HBe in the mother. J Med Virol. 1986;19(2):135–42.
28. Hyams KC, Okoth FA, Tukei PM, Mugambi M, Johnson B, Morrill JC, et al.
Epidemiology of hepatitis B in eastern Kenya. J Med Virol. 1989;28(2):106–9.
29. Beckerleg S, Telfer M, Hundt GL. The rise of injecting drug use in East Africa:
a case study from Kenya. Harm Reduct J. 2005;2:12.
30. Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, et al.
Impaired generation of hepatitis B virus-specific memory B cells in HIV
infected individuals following vaccination. Vaccine. 2010;28(21):3672–8.
31. Awoderu OB, Bandaru SA, Saliu OB, Oyebadejo SA, Omilabu SA. Hepatitis Be
Antigen (HBeAg) and Antibody (HBeAb) in Human Immunodeficiency Virus
(HIV) Seropositive Patients in Lagos, Nigeria. NJHBS, 2009;8(1):5-7.
32. Klusonova H, Stepanova V, Cizek J, Pliskova L. Viral hepatitis in users of
addictive drugs in the Czech Republic. Epidemiol Mikrobiol Imunol.
2004;53(2):47–54.
33. Franzeck FC, Ngwale R, Msongole B, Hamisi M, Abdul O, Henning L, et al. Viral
hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected
patients in rural Tanzania. PLoS One. 2013;8(3), e58468.
34. Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, et al.
Validation of rapid point-of-care (POC) tests for detection of hepatitis B
surface antigen in field and laboratory settings in the Gambia, Western
Africa. J Clin Microbiol. 2015;53(4):1156–63.
35. Bath GE, Scott TG, Sibbald CJ, Upton PA, Ramsay CN, Willocks LJ. Acute
hepatitis B in Edinburgh 1975–92: a retrospective study in a population
where human immunodeficiency virus is highly prevalent. Epidemiol Infect.
1997;119(1):85–9.
Webale et al. BMC Infectious Diseases  (2015) 15:299 Page 7 of 8
36. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of
chronic hepatitis B and incidence of acute hepatitis B infection in human
immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571–7.
37. Khodadoostan M, Ataei B, Shavakhi A, Tavakoli T, Nokhodian Z, Yaran M.
The assessment of hepatitis B seroprevalence in persons with intravenous
drug use history in the Isfahan province: Community-based study. J Res
Med Sci. 2014;19(1):65–8.
38. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and
correlates of HIV infection among young injection drug users in San
Francisco. J Acquir Immune Defic Syndr. 2002;31(4):422–31.
39. Mayaphi SH, Roussow TM, Masemola DP, Olorunju SA, Mphahlele MJ,
Martin DJ. HBV/HIV co-infection: the dynamics of HBV in South African
patients with AIDS. S Afr Med J. 2012;102(3 Pt 1):157–62.
40. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune
response to hepatitis B virus vaccination among HIV-1 infected and uninfected
adults in Kenya. J Infect Dis. 2013;207(3):402–10.
41. Cortez KJ, Proschan MA, Barrett L, Brust DG, Weatherley B, Formentini E,
et al. Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir
treatment in lamivudine-resistant HBV-infected patients with or without HIV
infection. HIV Clin Trials. 2014;14(4):149–59.
42. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A
comprehensive immunization strategy to eliminate transmission of hepatitis B
virus infection in the United States: recommendations of the Advisory
Committee on Immunization Practices (ACIP) Part II: immunization of adults.
MMWR Recomm Rep. 2006;55(RR-16):1–25.
43. WHO. Global Alert and Response (GAR) Hepatitis B 2015 [cited; Available
from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/
index3.html.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Webale et al. BMC Infectious Diseases  (2015) 15:299 Page 8 of 8
